We are live on ! Find out more
EDIT icon

Editas Medicine
EDIT

220 hedge funds and large institutions have $481M invested in Editas Medicine in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 76 increasing their positions, 62 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $6.11M | Put options by funds: $3.5M

23% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 62

2.27% less ownership

Funds ownership: 77.04% → 74.77% (-2.3%)

7% less capital invested

Capital invested by funds: $517M → $481M (-$35.8M)

7% less funds holding

Funds holding: 237 → 220 (-17)

38% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 40

Holders
220
Holders Change
-17
Holders Change %
-7.17%
% of All Funds
3.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
76
Reduced
62
Closed
40
Calls
$6.11M
Puts
$3.5M
Net Calls
+$2.61M
Net Calls Change
-$919K

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$31.3M
2
BlackRock
BlackRock
New York
+$4.84M
3
WP
Woodline Partners
California
+$4.38M
4
Squarepoint
Squarepoint
New York
+$4.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$24.7M
2
GCM
Ghisallo Capital Management
Massachusetts
-$8.02M
3
State Street
State Street
Massachusetts
-$7.47M
4
Man Group
Man Group
United Kingdom
-$6.35M
5
Marshall Wace
Marshall Wace
United Kingdom
-$5.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
AWM
176
Ameliora Wealth Management
Switzerland
$3.9K – – –
AF
177
Allworth Financial
California
$3.6K +$326 +38 +9%
First Manhattan
178
First Manhattan
New York
$3.46K – – –
WT
179
Washington Trust
Rhode Island
$3.45K – – –
GWM
180
Geneos Wealth Management
Colorado
$3.12K – – –
HI
181
Harbour Investments
Wisconsin
$2.64K -$617 -72 -18%
ICM
182
Islay Capital Management
Texas
$2.34K – – –
WT
183
Whittier Trust
California
$2.32K – – –
PWMG
184
Provence Wealth Management Group
California
$2.21K +$2.44K +284 New
BTI
185
Blue Trust Inc
Georgia
$2K – – –
LFG
186
Larson Financial Group
Missouri
$1.9K – – –
FHA
187
First Horizon Advisors
Tennessee
$1.79K – – –
HPC
188
HM Payson & Co
Maine
$1.64K – – –
BBPWM
189
Blue Bell Private Wealth Management
Pennsylvania
$1.4K – – –
SIS
190
Sound Income Strategies
Florida
$1.17K – – –
SWM
191
Spire Wealth Management
Virginia
$1.17K +$1.29K +150 New
LC
192
Lindbrook Capital
California
$1.08K -$17 -2 -1%
TFGT
193
TS Financial Group (TSFG)
Illinois
$1K – – –
HL
194
HeadInvest LLC
Maine
$942 +$1.13K +132 New
CSPIA
195
Cary Street Partners Investment Advisory
Virginia
$780 – – –
AF
196
Advisornet Financial
Minnesota
$741 – – –
LF
197
Lee Financial
Texas
$741 – – –
PA
198
Parallel Advisors
California
$725 – – –
KFI
199
Key Financial Inc
Pennsylvania
$671 – – –
BHWM
200
Beaird Harris Wealth Management
Texas
$624 – – –
6 7
8
9 10

EDIT Hedge Fund Activity: Q3 2023 in Review

220 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2023, worth a combined $481M — down 6.9% from $517M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of EDIT and 25 opened new positions — a net loss of 15 holders — while 62 trimmed existing stakes and 76 added.

The largest buyer was Deep Track Capital, adding an estimated $31.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $24.7M sold.

  • 220 institutional investors held Editas Medicine (EDIT) as of Q3 2023, down from 237 in Q2 2023.
  • Funds reported $481M of Editas Medicine stock for Q3 2023, down 6.9% quarter-over-quarter.
  • 25 funds opened new Editas Medicine positions in Q3 2023 and 40 closed out, a net change of -15 holders.
  • The largest Editas Medicine buyer in Q3 2023 was Deep Track Capital, an estimated $31.3M added.
  • The largest Editas Medicine seller in Q3 2023 was Avidity Partners Management, an estimated $24.7M sold.

Based on aggregated 13F filings for Q3 2023.